Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: Modulation of alternative pre-RNA splicing

Journal of Medicinal Chemistry

Volumn 54, Issue 12, 2011, Pages 4172-4186

  Debdab, Mansour ^a   Carreaux, François ^a   Renault, Steven ^a   Soundararajan, Meera ^b   Fedorov, Oleg ^b   Filippakopoulos, Panagis ^b   Lozach, Olivier ^c   Babault, Lucie ^c   Tahtouh, Tania ^c   Baratte, Blandine ^c   Ogawa, Yasushi ^d   Hagiwara, Masatoshi ^e   Eisenreich, Andreas ^f   Rauch, Ursula ^f   Knapp, Stefan ^b   Meijer, Laurent ^c   Bazureau, Jean Pierre ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c STATION BIOLOGIQUE   (France)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 [(1,3 BENZODIOXOL 5 YL)METHYLENE] 3 METHYL 2 (2 HYDROXYETHYL)AMINO 3,5 DIHYDRO 4H IMIDAZOL 4 ONE; 5 [(1,3 BENZODIOXOL 5 YL)METHYLENE] 3 METHYL 2 METHYLAMINO 3,5 DIHYDRO 4H IMIDAZOL 4 ONE; 5 [(1,3 BENZODIOXOL 5 YL)METHYLENE] 3 METHYL 2 PROPYLAMINO 3,5 DIHYDRO 4H IMIDAZOL 4 ONE; ALKALOID DERIVATIVE; CDC2 LIKE KINASE; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION ACTIVATED KINASE 1A; LEUCETTAMINE B; LEUCETTINE DERIVATIVE; MESSENGER RNA PRECURSOR; NATURAL PRODUCT; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; SERINE ARGININE RICH PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DOWN SYNDROME; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; RNA SPLICING;

EID: 79959406830     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200274d     Document Type: Article

References (78)

1. Kornprobst, J.-M. Encyclopedia of Marine Natural Products; Wiley: New York, 2010; Vol. 3, pp 1680.
2. Morris, J. C.; Phillips, A. J. Marine natural products: synthetic aspects Nat. Prod. Rep. 2010, 27, 1186-1203
3. Thomas, T. R.; Kavlekar, D. P.; LokaBharathi, P. A. Marine drugs from sponge-microbe association: a review Mar. Drugs 2010, 8, 1417-1468
4. Blunt, J. W.; Copp, B. R.; Munro, M. H.; Northcote, P. T.; Prinsep, M. R. Marine natural products Nat. Prod. Rep. 2010, 27, 165-237
5. Glaser, K. B.; Mayer, A. M. A renaissance in marine pharmacology: From preclinical curiosity to clinical reality Biochem. Pharmacol. 2009, 78, 440-448
6. Molinski, T. F.; Dalisay, D. S.; Lievens, S. L.; Saludes, J. P. Drug development from marine natural products Nat. Rev. Drug Discovery 2009, 8, 69-85
7. Waters, A. L.; Hill, R. T.; Place, A. R.; Hamann, M. T. The expanding role of marine microbes in pharmaceutical development Curr. Opin. Biotechnol. 2010, 21, 780-786
8. Mayer, A. M.; Rodríguez, A. D.; Berlinck, R. G.; Fusetani, N. Marine pharmacology in 2007-8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action Comp. Biochem. Physiol., Part C: Toxicol. Pharmacol. 2011, 153, 191-222
9. Villa, F. A.; Gerwick, L. Marine natural product drug discovery: Leads for treatment of inflammation, cancer, infections, and neurological disorders Immunopharmacol. Immunotoxicol. 2010, 32, 228-237
10. Mayer, A. M.; Glaser, K. B.; Cuevas, C.; Jacobs, R. S.; Kem, W.; Little, R. D.; McIntosh, J. M.; Newman, D. J.; Potts, B. C.; Shuster, D. E. The odyssey of marine pharmaceuticals: a current pipeline perspective Trends Pharmacol. Sci. 2010, 31, 255-265
11. Yasuhara-Bell, J.; Lu, Y. Marine compounds and their antiviral activities Antiviral Res. 2010, 86, 231-240
12. Chan, G. W.; Mong, S.; Hemling, M. E.; Freyer, A. J.; Offen, P. M.; De Brosse, C. W.; Sarau, H. M.; Westley, J. W. New leukotriene B4 receptor antagonist: leucettamine A and related imidazole alkaloids from the marine sponge Leucetta microraphis J. Nat. Prod. 1993, 56, 116-121 (Pubitemid 23066686)
13. Watanabe, K.; Tsuda, Y.; Iwashima, M.; Iguchi, K. A new bioactive triene aldehyde from the marine sponge Leucetta microraphis J. Nat. Prod. 2000, 63, 258-260 (Pubitemid 30126933)
14. Davis, R. A.; Aalbersberg, W.; Meo, S.; Moreira da Rocha, R.; Ireland, C. M. The isolation and synthesis of polyandrocarpamines A and B. Two new 2-aminoimidazolone compounds from the Fijian ascidian, Polyandrocarpa sp Tetrahedron Lett. 2002, 58, 3263-3269 (Pubitemid 34310329)
15. Davis, R. A.; Baron, P. S.; Neve, J. E.; Cullinane, C. A microwave-assisted stereoselective synthesis of polyandrocarpamines A and B Tetrahedron Lett. 2008, 50, 880-882
16. Lindel, T.; Hoffmann, H. Synthesis of dispacamide from the marine sponge Agelas dispar Tetrahedron Lett. 1997, 38, 8935-8938 (Pubitemid 27526185)
17. Fresneda, P. M.; Molina, P.; Sanz, M. A. A convergent approach to midpacamide and dispacamide pyrrole-imidazole marine alkaloids Tetrahedron Lett. 2001, 42, 851-854 (Pubitemid 32119392)
18. Travert, N.; Al-Mourabit, A. A likely biogenetic gateway linking 2-aminoimidazolinone metabolites of sponges to proline: spontaneous oxidative conversion of the pyrrole-proline-guanidine pseudo-peptide to dispacamide A J. Am. Chem. Soc. 2004, 126, 10252-10253 Erratum in: J. Am. Chem. Soc. 2005, 127, 10454. (Pubitemid 39100771)
19. Hollenbeak, K. H.; Schmitz, F. J. Aplysinopsin: antineoplastic tryptophan derivative from the marine sponge Verongia spengelii Lloydia 1977, 40, 479-481
20. Singh, S. N.; Bhatnagar, S.; Fatma, N.; Chauhan, P. M.; Chatterjee, R. K. Antifilarial activity of a synthetic marine alkaloid, aplysinopsin (CDRI Compound 92/138) Trop. Med. Int. Health 1997, 2, 535-543 (Pubitemid 27304332)
21. Cimino, G.; de Rosa, S.; de Stefano, S.; Mazzarella, L.; Puliti, R.; Sodano, G. Isolation & X-ray crystal structure of a novel bromo-compound from two marine sponges Tetrahedron Lett. 1982, 23, 767-768
22. Sharma, G. M.; Buyer, J.; Pomerantz, M. W. Characterization of a yellow compound isolated from the marine sponge Phakellia flabellata J. Chem. Soc. Chem. Commun. 1980, 10, 435-436
23. Williams, D. H.; Faulkner, J. Isomers and tautomers of hymenialdisine and debromohymenialdisine Nat. Prod. Lett. 1996, 9, 57-64 (Pubitemid 26395328)
24. Xu, Y. Y.; Yakushijin, K.; Horne, D. A. Synthesis of C(11)N(5) Marine sponge alkaloids: (±)-hymenin, stevensine, hymenialdisine, and debromohymenialdisine J. Org. Chem. 1997, 62, 456-464
25. Papeo, G.; Posteri, H.; Borghi, D.; Varasi, M. A new glycociamidine ring precursor: syntheses of (Z)-hymenialdisine, (Z)-2-debromohymenialdisine, and (±)-endo-2-debromohymenialdisine Org. Lett. 2005, 7, 5641-5644 (Pubitemid 43010818)
26. Nguyen, T. N.; Tepe, J. J. Preparation of hymenialdisine, analogues and their evaluation as kinase inhibitors Curr. Med. Chem. 2009, 16, 3122-3143
27. Meijer, L.; Thunnissen, A. M. W. H.; White, A.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S.-H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3β and casein kinase 1 by hymenialdisine, a marine sponge constituent Chem. Biol. 2000, 7, 51-63 (Pubitemid 30141925)
28. Wan, Y.; Hur, W.; Cho, C. Y.; Liu, Y.; Adrian, F. J.; Lozach, O.; Bach, S.; Mayer, T.; Fabbro, D.; Meijer, L.; Gray, N. S. Synthesis and target identification of hymenialdisine analogs Chem. Biol. 2004, 11, 247-259 (Pubitemid 38305843)
29. Tasdemir, D.; Mallon, R.; Greenstein, M.; Feldberg, L. R.; Kim, S. C.; Collins, K.; Wojciechowicz, D.; Mangalindan, G. C.; Concepción, G. P.; Harper, M. K.; Ireland, C. M. Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1) J. Med. Chem. 2002, 45, 529-532 (Pubitemid 34073469)
30. Sharma, V.; Tepe, J. J. Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine Bioorg. Med. Chem. Lett. 2004, 14, 4319-4321 (Pubitemid 38922849)
31. Parmentier, J. G.; Portevin, B.; Golsteyn, R. M.; Pierré, A.; Hickman, J.; Gloanec, P.; De Nanteuil, G. Synthesis and CHK1 inhibitory potency of Hymenialdisine analogues Bioorg. Med. Chem. Lett. 2009, 19, 841-844
32. Molina, P.; Almendros, P.; Fresneda, P. M. An iminophosphorane-mediated efficient synthesis of the alkaloid leucettamine B of marine of origin Tetrahedron Lett. 1994, 35, 2235-2236 (Pubitemid 24118879)
33. Roué, N.; Bergman, J. Synthesis of the marine alkaloid leucettamine B Tetrahedron 1999, 55, 14729-14738
34. Chérouvrier, J. R.; Boissel, J.; Carreaux, F.; Bazureau, J. P. A stereoselective route to 3-methyl-2-methylsulfanyl-5-yliden-3,4-dihydro- imidazol-4-one derivatives and precursor of Leucettamine B Green Chem. 2001, 3, 165-169
35. Chérouvrier, J. R.; Carreaux, F.; Bazureau, J. P. Microwave-mediated solventless synthesis of new derivatives of marine alkaloid Leucettamine B Tetrahedron Lett. 2002, 43, 3581-3584 (Pubitemid 34442361)
36. Debdab, M.; Renault, S.; Eid, S.; Lozach, O.; Meijer, L.; Carreaux, F.; Bazureau, J.-P. An efficient method for the preparation of new analogs of leucettamine B under solvent-free microwave irradiation Tetrahedron Let. 2009, 78, 1191-1203
37. Hagiwara, M. Alternative splicing: a new drug target of the post-genome era Biochim. Biophys. Acta 2005, 1754, 324-331 (Pubitemid 41797714)
38. Aranda, S.; Laguna, A.; de la Luna, S. DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles FASEB J. 2011, 25, 449-462
39. Kimura, R.; Kamino, K.; Yamamoto, M.; Nuripa, A.; Kida, T.; Kazui, H.; Hashimoto, R.; Tanaka, T.; Kudo, T.; Yamagata, H.; Tabara, Y.; Miki, T.; Akatsu, H.; Kosaka, K.; Funakoshi, E.; Nishitomi, K.; Sakaguchi, G.; Kato, A.; Hattori, H.; Uema, T.; Takeda, M. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease Hum. Mol. Genet. 2007, 16, 15-23 (Pubitemid 46152541)
40. Ryoo, S. R.; Jeong, H. K.; Radnaabazar, C.; Yoo, J. J.; Cho, H. J.; Lee, H. W.; Kim, I. S.; Cheon, Y. H.; Ahn, Y. S.; Chung, S. H.; Song, W. J. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease J. Biol. Chem. 2007, 282, 34850-34857 (Pubitemid 350232475)
41. Ryoo, S. R.; Cho, H. J.; Lee, H. W.; Jeong, H. K.; Radnaabazar, C.; Kim, Y. S.; Kim, M. J.; Son, M. Y.; Seo, H.; Chung, S. H.; Song, W. J. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimers disease J. Neurochem. 2008, 104, 1333-1344 (Pubitemid 351293338)
42. Ryu, Y. S.; Park, S. Y.; Jung, M. S.; Yoon, S. H.; Kwen, M. Y.; Lee, S. Y.; Choi, S. H.; Radnaabazar, C.; Kim, M. K.; Kim, H.; Kim, K.; Song, W. J.; Chung, S. H. Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimers disease J. Neurochem. 2010, 115, 574-584
43. Sitz, J. H.; Baumgärtel, K.; Hämmerle, B.; Papadopoulos, C.; Hekerman, P.; Tejedor, F. J.; Becker, W.; Lutz, B. The Down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4 Neuroscience 2008, 157, 596-605
44. Glatz, D. C.; Rujescu, D.; Tang, Y.; Berendt, F. J.; Hartmann, A. M.; Faltraco, F.; Rosenberg, C.; Hulette, C.; Jellinger, K.; Hampel, H.; Riederer, P.; Möller, H. J.; Andreadis, A.; Henkel, K.; Stamm, S. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimers disease J. Neurochem. 2006, 96, 635-644
45. Wegiel, J.; Kaczmarski, W.; Barua, M.; Kuchna, I.; Nowicki, K.; Wang, K. C.; Wegiel, J.; Yang, S. M.; Frackowiak, J.; Mazur-Kolecka, B.; Silverman, W. P.; Reisberg, B.; Monteiro, I.; de Leon, M.; Wisniewski, T.; Dalton, A.; Lai, F.; Hwang, Y. W.; Adayev, T.; Liu, F.; Iqbal, K.; Iqbal, I. G.; Gong, C. X. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome J. Neuropathol. Exp. Neurol. 2011, 70, 36-50
46. Ding, S.; Shi, J.; Qian, W.; Iqbal, K.; Grundke-Iqbal, I.; Gong, C. X.; Liu, F. Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A. Neurobiol. Aging 2011, in press.
47. Liu, F.; Gong, C. X. Tau exon 10 alternative splicing and taupathies. Mol. Neurodegenertaion 2008, 3
48. Wegiel, J.; Dowjat, K.; Kaczmarski, W.; Kuchna, I.; Nowicki, K.; Frackowiak, J.; Mazur Kolecka, B.; Wegiel, J.; Silverman, W. P.; Reisberg, B.; Deleon, M.; Wisniewski, T.; Gong, C. X.; Liu, F.; Adayev, T.; Chen-Hwang, M. C.; Hwang, Y. W. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome Acta Neuropathol. 2008, 116, 391-407
49. Park, J.; Oh, Y.; Chung, K. C. Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1 BMB Rep. 2009, 42, 6-15
50. Shi, J.; Zhang, T.; Zhou, C.; Chohan, M. O.; Gu, X.; Wegiel, J.; Zhou, J.; Hwang, Y. W.; Iqbal, K.; Grundke-Iqbal, I.; Gong, C. X.; Liu, F. Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome J. Biol. Chem. 2008, 283, 28660-28669
51. Noll, C.; Planque, C.; Ripoll, C.; Guedj, F.; Diez, A.; Ducros, V.; Belin, N.; Duchon, A.; Paul, J. L.; Badel, A.; de Freminville, B.; Grattau, Y.; Bléhaut, H.; Herault, Y.; Janel, N.; Delabar, J. M. DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase PLoS One 2009, 4, e7540
52. Roué, N.; Bergman, J. Synthesis of the marine alkaloid leucettamine B Tetrahedron 1999, 55, 14729-14738
53. Bourgeois, C. F.; Lejeune, F.; Stévenin, J. Broad specificity of SR (serine/arginine) proteins in the regulation of alternative splicing of pre-messenger RNA Prog. Nucleic Acid Res. Mol. Biol. 2004, 78, 37-88 (Pubitemid 39753917)
54. Prasad, J.; Colwill, K.; Pawson, T.; Manley, J. L. The protein kinase Clk/Sty directly modulates SR protein activity: both hyper- and hypophosphorylation inhibit splicing Mol. Cell. Biol. 1999, 19, 6991-7000 (Pubitemid 29441881)
55. Fedorov, O.; Huber, K.; Eisenreich, A.; Filippakopoulos, P.; King, O.; Bullock, A. N.; Fabro, D.; Trappe, J.; Rauch, U.; Bracher, F.; Knapp, S. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing Chem. Biol. 2011, 18, 67-76
56. Eisenreich, A.; Bogdanov, V. Y.; Zakrzewicz, A.; Pries, A.; Antoniak, S.; Poller, W.; Schultheiss, H. P.; Rauch, U. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells Circ. Res. 2009, 104, 589-599
57. Muraki, M.; Ohkawara, B.; Hosoya, T.; Onogi, H.; Koizumi, J.; Koizumi, T.; Sumi, K.; Yomoda, J.; Murray, M. V.; Kimura, H.; Furuichi, K.; Shibuya, H.; Krainer, A. R.; Suzuki, M.; Hagiwara, M. Manipulation of alternative splicing by a newly developed inhibitor of Clks J. Biol. Chem. 2004, 279, 24246-2454
58. Yomoda, J.; Muraki, M.; Kataoka, N.; Hosoya, T.; Suzuki, M.; Hagiwara, M.; Kimura, H. Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A Genes Cells 2008, 13, 233-244 (Pubitemid 351292279)
59. Bain, J.; Plater, L.; Elliott, M.; Shapiro, N.; Hastie, C. J.; McLauchlan, H.; Klevernic, I.; Arthur, J. S.; Alessi, D. R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update Biochem. J. 2007, 408, 297-315
60. Göckler, N; Jofre, G; Papadopoulos, C; Soppa, U; Tejedor, F. J.; Becker, W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation FEBS J. 2009, 276, 6324-6337
61. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J. P. J.; Blow, J. J.; Inagaki, N.; Inagaki, M.; Delcros, J. G.; Moulinoux, J. P. Biochemical and cellular effects of roscovitine a potent and selective inhibitor of the cyclin-dependent kinases cdc2 cdk2 and cdk5 Eur. J. Biochem. 1997, 243, 527-36 (Pubitemid 27060443)
62. Meijer, L.; Raymond, E. Roscovitine and other purines as kinase inhibitors: from starfish oocytes to clinical trials Acc. Chem. Res. 2003, 36, 417-425
63. Black, D. L. Mechanisms of alternative pre-messenger RNA splicing Annu. Rev. Biochem. 2003, 72, 291-336 (Pubitemid 36930448)
64. Eisenreich, A.; Boltzen, U.; Poller, W.; Schultheiss, H. P.; Rauch, U. Effects of the Cdc2-like kinase-family and DNA topoisomerase I on the alternative splicing of eNOS in TNF-alpha-stimulated human endothelial cells Biol. Chem. 2008, 389, 1333-1338
65. Nowak, D. G.; Woolard, J.; Amin, E. M.; Konopatskaya, O.; Saleem, M. A.; Churchill, A. J.; Ladomery, M. R.; Harper, S. J.; Bates, D. O. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors J. Cell Sci. 2008, 121, 3487-3495
66. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Biernat, J.; Mandelkow, E.-M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two kinases involved in abnormal tau phosphorylation in Alzheimers disease-A property common to most CDK inhibitors ? J. Biol. Chem. 2001, 276, 251-260 (Pubitemid 32050314)
67. Primot, A.; Baratte, B.; Gompel, M.; Borgne, A.; Liabeuf, S.; Romette, J. L.; Costantini, F.; Meijer, L. Purification of GSK-3 by affinity chromatography on immobilised axin Protein Expression Purif. 2000, 20, 394-404
68. Reinhardt, J.; Ferandin, Y.; Meijer, L. Purification CK1 by affinity chromatography on immobilised axin Protein Expression Purif. 2007, 54, 101-109 (Pubitemid 46636329)
69. Leslie, A. G. W.; Powell, H. MOSFLM; MRC Laboratory of Molecular Biology: Cambridge, England, 2007.
70. Evans, P. SCALA: Scale Together Multiple Observations of Reflections; MRC Laboratory of Molecular Biology: Cambridge, england, 2007.
71. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Macromolecular Crystallography, Part A; Academic Press: New York, 1997; pp 307-326. (Pubitemid 27085611)
72. McCoy, A. J.; Grosse-Kunstleve, R. W.; Storoni, L. C.; Read, R. J. Likelihood enhanced fast translation functions Acta Crystallogr., Sect. D 2005, 61, 458-464 (Pubitemid 43934606)
73. Bullock, A. N.; Das, S.; Debreczeni, J. E.; Rellos, P.; Fedorov, O.; Niesen, F. H.; Guo, K.; Papagrigoriou, E.; Amos, A. L.; Cho, S.; Turk, B. E.; Ghosh, G.; Knapp, S. Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation Structure 2009, 17, 352-362
74. Perrakis, A.; Morris, R.; Lamzin, V. S. Automated protein model building combined with iterative structure refinement Nat. Struct. Biol. 1999, 6, 458-463 (Pubitemid 29218016)
75. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D 2004, 60, 2126-2132 (Pubitemid 41742764)
76. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D 1997, 53, 240-255 (Pubitemid 27235885)
77. Szotowski, B.; Goldin-Lang, P.; Antoniak, S.; Bogdanov, V. Y.; Pathirana, D.; Pauschinger, M.; Dörner, A.; Kuehl, U.; Coupland, S.; Nemerson, Y.; Hummel, M.; Poller, W.; Hetzer, R.; Schultheiss, H. P.; Rauch, U. Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy J. Am. Coll. Cardiol. 2005, 45, 1081-1089 (Pubitemid 40432443)
78. Hernández, F.; Gómez de Barreda, E.; Fuster-Matanzo, A.; Lucas, J. J.; Avila, J. GSK3: a possible link between beta amyloid peptide and tau protein Exp. Neurol. 2010, 223, 322-325